Tech Company Financing Transactions
Maze Therapeutics Funding Round
Maze Therapeutics closed a $190 million funding round on 1/11/2022. Backers included Matrix Capital Management, Andreessen Horowitz and Casdin Capital.
Transaction Overview
Company Name
Announced On
1/11/2022
Transaction Type
Venture Equity
Amount
$190,000,000
Round
Undisclosed
Investors
Proceeds Purpose
Proceeds from the financing will be used to support advancement of the company's nine precision medicines programs for both rare and common genetically defined diseases with high unmet need.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
131 Oyster Point Blvd. 200
San Francisco, CA 94080
USA
San Francisco, CA 94080
USA
Phone
Undisclosed
Website
Email Address
Overview
Maze Therapeutics is translating novel genetic insights into lifesaving medicines, through an approach that integrates human genetics and functional genomics. Advances in these areas have enabled us to decode the mysteries of genetic modifiers in a range of severe diseases, which we aim to turn into medicines that mimic protective mutations.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chairman
Charles Homcy
President
Jason Coloma
Vice President
Timothy Behrens
Vice President
Matthew Brauer
Vice President
David Morgans
VP - Bus. Development
Tara Nickerson
VP - R & D
Eric Green
Browse more venture capital transactions:
Prev: 1/11/2022: Syntegra venture capital transaction
Next: 1/11/2022: Avenge Bio venture capital transaction
Share this article
About Our VC Transactions Data
We report on every notable VC transaction. VC investment data records reported here are sourced from news reports and company announcements. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs